Euronext N : Affluent Medical lists on Euronext Paris
06/14/2021 | 06:36am EDT
Contact Investor Relations
20 721 4133
+32 2 620 15 50
+33 1 70 48 24 27
+353 1 617 4249
+351 210 600 614
02 72 42 62 12
+47 22 34 19 15
1 70 48 24 45
Affluent Medical lists on Euronext Paris
€25 million raised - market capitalisation of over €156 million
Paris - 14 June 2021 - Euronext today congratulates Affluent Medical, a French MedTech company specialising in the international development and industrialisation of innovative clinical- stage medical prostheses for the treatment of urinary incontinence and mitral valve pathology, on its listing on Compartment B of Euronext's regulated market in Paris (ticker code: AFME). Euronext is the number one listing venue for MedTech companies in Europe.
Founded by Truffle Capital, Affluent Medical aims to become a global benchmark player in the field of urology and interventional cardiology. Affluent Medical develops innovative, next-generation, minimally invasive implants to restore critical physiological functions in these areas. Affluent Medical's three medical devices are currently in the clinical phase and, following regulatory approval and CE marking, are expected to be launched rapidly in their respective target markets.
Affluent Medical was listed through the admission to trading of the 18,163,802 shares making up its equity and of 2,906,978 new shares issued under a Global Offering1.
The admission and issue price of Affluent Medical shares was set at €8.60 per share. Market capitalisation was €156.2 million on the day of listing. The offering raised €25 million altogether.
The Offer was successful with institutional, international and individual investors, with a total demand amounting to 2,906,978 shares, of which 72% were under the global placement and 28% under the open price offer (through 4,771 retail investors, representing a demand of €7 million).
Michel Finance, CEO and Chairman of Affluent Medical, said: "I would like to thank all of our new shareholders, individual and institutional, as well as our current shareholders, in particular Truffle Capital, who have shown their trust in us by contributing to the success of our initial public offering. I would also like to express a special thank you to our employees who, through their involvement and trust, make Affluent Medical a success every day. The funds raised provide us with the necessary means to pursue our development plan and to support the launch of our various innovative medical devices on the market. The first revenues are already expected in 2023 with the commercialisation of Kalios in Europe. Our ambition is to rapidly become a global MedTech player in the service of a better quality of life for millions of patients suffering from urinary incontinence and cardiac mitral valve pathology."
1 The Global Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.
| Page 1 of 3
Caption: Michel Finance, CEO and Chairman of Affluent Medical, and his team rang the bell during a virtual ceremony this morning together with Camille Leca, Head of Listing France at Euronext, to celebrate the Initial Public Offering of the company.
Thomas Roborel de Climens (Corporate Press Relations, DGM)
About Affluent Medical
+33 1 86 26 68 17
+33 6 47 97 54 87
+33 1 70 48 24 45
Affluent Medical is a French clinical-stage MedTech developing a portfolio of innovative medical prostheses that mimic human physiology to treat urinary incontinence and cardiac mitral insufficiency. Affluent Medical's product portfolio currently includes three prostheses and a technology protected by 31 patent families, addressing global and fast- growing markets, estimated to be worth €10 billion by 2027(1). These three products, whose initial development stages have been completed, with major investments made and positive pre-clinical and clinical results already obtained, aim to enter the market soon, subject to regulatory approval and CE marking. In order to conquer the European, American and Asian markets, Affluent Medical is targeting the first revenues from Kalios sales in Europe in 2023(2).
Market estimates calculated by the company based on the following studies: Urinary Incontinence Devices (Optima Insights) / Transcatheter Mitral Valve Implantation MarketSize (EmergenResearch) / Global Aortic Aneurysm Market (Infoholic Research).
Subject to the achievement of additional clinical development milestones and the obtaining of the necessary financing for the Company's development.
| Page 2 of 3
Euronext is the leading pan-European market infrastructure, connecting local economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With close to 1,900 listed issuers worth €5.6 trillion in market capitalisation as of end March 2021, it has an unmatched blue chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe's leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs. Euronext provides custody and settlement services through central securities depositories in Denmark, Italy, Norway and Portugal.
This press release is for information purposes only: it is not a recommendation to engage in investment activities and is provided "as is", without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext's subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext. This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is available at www.euronext.com/terms-use.
The Euronext Group processes your personal data in order to provide you with information about Euronext (the "Purpose"). With regard to the processing of this personal data, Euronext will comply with its obligations under Regulation (EU) 2016/679 of the European Parliament and Council of 27 April 2016 (General Data Protection Regulation, "GDPR"), and any applicable national laws, rules and regulations implementing the GDPR, as provided in its privacy statement available at: www.euronext.com/privacy-policy.In accordance with the applicable legislation you have rights with regard to the processing of your personal data: for more information on your rights, please refer to: www.euronext.com/data_subjects_rights_request_information. To make a request regarding the processing of your data or to unsubscribe from this press release service, please use our data subject request form at connect2.euronext.com/form/data-subjects-rights-request or email our Data Protection Officer at email@example.com.